TRANSACTION RECORD

DOWNLOAD RECORD   vCard | CSV | PDF
Company Name IM Therapeutics
Status Private & Independent
Industry Biopharmaceutical
Company Description IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development.
Mailing Address 299 Washington St. Suite A
Woburn, MA 01801
USA  Map
Phone (303) 544-2104
Website www.imtherapeutics.com
Email Click for Free Trial
Profile
Social Media
Company News
Facebook
YouTube
 
Company Management
Title Name Email Profile
     
Chief Executive Officer Padukone, Nandan
Chief Scientific Officer Michels, Aaron
Chief Medical Officer Gottlieb, Peter
VP - R & D Perni, Robert
Information Release Date 10/10/2019
Transaction Type Venture Equity
Amount $10,000,000
Round Series A
Proceeds Purposes Funding will Advance Lead Drug in Type 1 Diabetes and Develop HLA-Targeted Therapeutic Platform in Autoimmune Disorders
Transaction Investors
JDRF T1D Fund
(Lead Investor)
Sean Doherty
Morningside Group
(Lead Investor)
Jason Dinges
CU Healthcare Innovation Fund

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.


PCI - Level1